Ribomic News

Ribomic: Notice regarding the monthly exercise status of the 17th Stock Acquisition Rights (with exercise price amendment clause)

Jan 6 01:30 ET

Ribomic: Notice of completion of the observation period for the final case in the first phase II observational trial of an achondroplasia treatment drug (umedaptanib pegol)

Dec 25, 2024 01:30 ET

Ribomic: Dengue virus inhibitors: development of aptamer-siRNA complex “chimeric nucleic acid”

Dec 24, 2024 01:30 ET

Ribomic: Change Report (Stock Certificates Eligible for Special Provisions, etc.)

Dec 5, 2024 22:50 ET

Ribomic: A transcript of our financial results briefing for the 2nd quarter (interim period) of the fiscal year ending 2025/3 was published on Logme Finance

Dec 3, 2024 01:30 ET

Ribomic: Notice regarding the monthly exercise status of the 17th Stock Acquisition Rights (with exercise price amendment clause)

Dec 2, 2024 01:30 ET

Ribomic: Notice of video distribution of the financial results briefing for the 2nd quarter (interim period) of the fiscal year ending 2025/3

Nov 27, 2024 01:30 ET

Ribomic: Financial results briefing for the 2nd quarter (interim period) of the fiscal year ending 2025/3 (Q & A)

Nov 22, 2024 01:30 ET

Ribomic: Financial results briefing materials for the 2nd quarter (interim period) of the fiscal year ending 2025/3

Nov 20, 2024 04:00 ET

Ribomic: Notice of patent assessment in Taiwan for application patents relating to umedaptanib pegol (anti-FGF2 aptamer)

Nov 19, 2024 01:30 ET

Ribomic: Notice regarding presentation of research results for quantum and AI next-generation drug discovery

Nov 15, 2024 01:30 ET

Ribomic: Notice of MOU signing with King Abdullah International Medical Research Center

Nov 13, 2024 01:30 ET

Ribomic: Confirmatory letter.

Nov 12, 2024 20:14 ET

Ribomic: Half Year Report - Term 22 (2024/04/01 - 2025/03/31)

Nov 12, 2024 20:13 ET

Ribomic: Summary of Non-Consolidated Financial Results for the Six Months Ended September 30 2024(Based on Japanese GAAP)

Nov 12, 2024 01:30 ET

Ribomic: Summary of financial results for the 2nd quarter (interim period) of the fiscal year ending 2025/3 [Japanese GAAP] (unconsolidated)

Nov 12, 2024 01:30 ET

Ribomic: Notice regarding the recording of non-operating income (grant revenue) and non-operating losses (exchange losses)

Nov 12, 2024 01:30 ET

Ribomic: Notice of confirmation of remarkable effects (increase in growth rate) in the low dose group in early phase II clinical trials for achondroplasia (umedaptanib pegol)

Nov 5, 2024 01:30 ET

Ribomic: Notice regarding the monthly exercise status of the 17th Stock Acquisition Rights (with exercise price amendment clause)

Nov 1, 2024 02:00 ET

Ribomic: Announcement of invited talks at The Riyadh Global Medical Biotechnology Summit

Oct 24, 2024 02:00 ET